UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2007
Lexicon Genetics Incorporated
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
000-30111
(Commission File Number)
|
|
76-0474169
(I.R.S. Employer
Identification Number) |
8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive
offices and Zip Code)
(281) 863-3000
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(e) On February 13, 2007, the Compensation Committee of our Board of Directors approved
2007 base salaries and a process for the determination of 2007 cash bonuses for our named executive
officers. The 2007 salary information and a description of the 2007 cash bonus determination
process is attached to this current report on Form 8-K as Exhibit 10.1 and incorporated herein by
reference.
The Compensation Committee also approved the payment of 2006 cash bonuses to our named
executive officers as described below:
| |
|
|
| |
|
2006 |
| Name and Position |
|
Cash Bonus |
|
|
|
Arthur T. Sands, M.D., Ph.D.
President and Chief Executive Officer |
|
$300,000 |
Julia P. Gregory
Executive Vice President, Corporate Development
and Chief Financial Officer |
|
$80,000 |
Alan J. Main, Ph.D.
Executive Vice President of Pharmaceutical Research |
|
$90,000 |
Jeffrey L. Wade, J.D.
Executive Vice President and General Counsel |
|
$80,000 |
Brian P. Zambrowicz, Ph.D.
Executive Vice President and Chief Scientific Officer |
|
$120,000 |
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| |
|
|
|
|
| Exhibit No. |
|
|
|
Description |
|
|
|
|
|
10.1
|
|
—
|
|
Summary of 2007 Named Executive Officer Cash Compensation |